[
  {
    "ts": null,
    "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
    "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
    "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757962258,
      "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
      "id": 136767795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428756484/image_1428756484.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
      "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182"
    }
  },
  {
    "ts": null,
    "headline": "National Association of Specialty Pharmacy Congratulates Industry Award Winners at its Record-Breaking 2025 Annual Meeting & Expo",
    "summary": "Washington, DC, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) announces Industry Award winners at its record-breaking 2025 Annual Meeting & Expo in Denver, CO. The peer-nominated and reviewed industry awards are presented to the individuals and organizations that have helped to advance patient care and the practice of specialty pharmacy, as well as upheld the values of NASP over the past year. NASP congratulated the winners of the Specialty Pharmacy of",
    "url": "https://finnhub.io/api/news?id=6548271faf9ee35c3063d2648c261cc7caf86541098f486b48dde132a5c53a7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757956320,
      "headline": "National Association of Specialty Pharmacy Congratulates Industry Award Winners at its Record-Breaking 2025 Annual Meeting & Expo",
      "id": 136766008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Washington, DC, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) announces Industry Award winners at its record-breaking 2025 Annual Meeting & Expo in Denver, CO. The peer-nominated and reviewed industry awards are presented to the individuals and organizations that have helped to advance patient care and the practice of specialty pharmacy, as well as upheld the values of NASP over the past year. NASP congratulated the winners of the Specialty Pharmacy of",
      "url": "https://finnhub.io/api/news?id=6548271faf9ee35c3063d2648c261cc7caf86541098f486b48dde132a5c53a7c"
    }
  },
  {
    "ts": null,
    "headline": "Arbutus: IP Drama With High Stakes",
    "summary": "Discover the latest on Arbutus Biopharmaâs patent litigation strategy and investment risks. Learn if ABUS is a speculative hold ahead of key 2026 outcomes.",
    "url": "https://finnhub.io/api/news?id=e0d55e7cd91607eef3cf2f8433c6b0143680c5ec530f1218f739885b1d222f87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757953650,
      "headline": "Arbutus: IP Drama With High Stakes",
      "id": 136766534,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1130708325/image_1130708325.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover the latest on Arbutus Biopharmaâs patent litigation strategy and investment risks. Learn if ABUS is a speculative hold ahead of key 2026 outcomes.",
      "url": "https://finnhub.io/api/news?id=e0d55e7cd91607eef3cf2f8433c6b0143680c5ec530f1218f739885b1d222f87"
    }
  },
  {
    "ts": null,
    "headline": "CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?",
    "summary": "CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.",
    "url": "https://finnhub.io/api/news?id=3be096b32faf038104c255df7bbcaaa216d0d3eb060b888052976b36e89cfea8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757950020,
      "headline": "CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?",
      "id": 136766009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.",
      "url": "https://finnhub.io/api/news?id=3be096b32faf038104c255df7bbcaaa216d0d3eb060b888052976b36e89cfea8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=cd26a8b534d4cdcd63fd7b7249a21ec4a2d131fc89f7fe7140c5ad4413cd1aeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944803,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136766010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=cd26a8b534d4cdcd63fd7b7249a21ec4a2d131fc89f7fe7140c5ad4413cd1aeb"
    }
  },
  {
    "ts": null,
    "headline": "Saisei Ventures Appoints James Feliciano as Venture Partner",
    "summary": "CAMBRIDGE, Mass., September 15, 2025--Saisei Ventures, a leading investment firm focused on advancing Japanese biotechnology and therapeutic innovations, today announced that Mr. James Feliciano has been appointed venture partner.",
    "url": "https://finnhub.io/api/news?id=bb959f91b472dee3dfa94b48aeabb3111a693e62ca5aca918bad41befc636497",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944800,
      "headline": "Saisei Ventures Appoints James Feliciano as Venture Partner",
      "id": 136749536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., September 15, 2025--Saisei Ventures, a leading investment firm focused on advancing Japanese biotechnology and therapeutic innovations, today announced that Mr. James Feliciano has been appointed venture partner.",
      "url": "https://finnhub.io/api/news?id=bb959f91b472dee3dfa94b48aeabb3111a693e62ca5aca918bad41befc636497"
    }
  },
  {
    "ts": null,
    "headline": "COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths",
    "summary": "MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.",
    "url": "https://finnhub.io/api/news?id=c145a4cde7fe21b8a3caaca09df19b7f3e003f180cf0c31a6595b8210f6aa919",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944560,
      "headline": "COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths",
      "id": 136766011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.",
      "url": "https://finnhub.io/api/news?id=c145a4cde7fe21b8a3caaca09df19b7f3e003f180cf0c31a6595b8210f6aa919"
    }
  },
  {
    "ts": null,
    "headline": "How Bad Is This Sector’s Health Scare?",
    "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
    "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757937307,
      "headline": "How Bad Is This Sector’s Health Scare?",
      "id": 136749580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
      "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3"
    }
  },
  {
    "ts": null,
    "headline": "Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc",
    "summary": "Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinical drug candidate discovered from Oncology One's out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical trial, a key milestone.",
    "url": "https://finnhub.io/api/news?id=870668021d940a9c4681c0f858900e948638d5d306f5c1d0344413e4fde9ab01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757912760,
      "headline": "Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc",
      "id": 136749650,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinical drug candidate discovered from Oncology One's out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical trial, a key milestone.",
      "url": "https://finnhub.io/api/news?id=870668021d940a9c4681c0f858900e948638d5d306f5c1d0344413e4fde9ab01"
    }
  }
]